Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. Nov 15, 2023; 15(11): 1874-1890
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1874
Table 4 Six-month conditional cancer-specific survival rates of patients with distant-metastatic hepatocellular carcinoma
CharacteristicsCancer-specific survival (months after diagnosis)
0
d
2
d
4
d
6
d
Overall34.7742.4848.655.11
Age, yr
    < 5532.0543.3653.1966.41
    55-65360.0841.63-0.0445.44-0.1642.52-0.48
    ≥ 6534.790.0643.05-0.0150.09-0.0656.97-0.19
Gender
    Female36.6745.7654.6458.38
    Male34.35-0.0541.77-0.0847.24-0.1554.33-0.08
Race
    Black36.2243.2449.2255.84
    White36.310.0044.260.0249.360.0056.340.01
    Other28.31-0.1735.2-0.1644.84-0.0950.3-0.11
Marital status
    Married34.0141.8247.3755.74
    Single35.150.0243.060.0352.070.0954.74-0.02
    Separated360.0443.250.0347.460.0054.23-0.03
AFP expression
    Positive32.7544.9445.351.21
    Negative45.670.2751.740.1462.820.35700.38
Tumor size
    ≤ 5 cm40.7951.8864.0762.94
    > 5 cm32.51-0.1738.86-0.2642.46-0.4351.42-0.23
T stage
    T141.6650.3257.8862.8
    T240.4-0.0351.470.0259.430.0357.77-0.10
    T330.68-0.2336.49-0.2842.85-0.3051.69-0.22
    T432.82-0.1940.66-0.2038.16-0.3946.15-0.33
N stage
    N036.4844.751.3662.39
    N131.00-0.1237.11-0.1541.57-0.2044.53-0.36
Surgery
    No32.6939.8145.8452.64
    Yes69.510.7773.970.6974.60.5873.60.42
Chemotherapy
    No/unknown24.0537.5248.0556.21
    Yes43.680.4145.050.1548.870.0254.64-0.03
Radiotherapy
    No/unknown30.9239.747.6655.55
    Yes49.750.4050.720.22510.0754.05-0.03
Lung metastasis
    No40.6946.0249.3353.7
    Yes24.4-0.3434.24-0.2446.61-0.0559.180.11
Bone metastasis
    No33.5241.0348.155.99
    Yes37.840.0945.870.1049.790.0353.21-0.06
Brain metastasis
    No34.8342.548.5954.78
    Yes31.91-0.0642.48-0.000448.610.000464.460.19